Skip to main content

Advertisement

Table 3 Comparison of median and interquartile range (IQR) of plasma efavirenz (EFV) concentrations (mg/L) between patients who presented with any neuropsychiatric disorders (Yes) and who did not (No) during efavirenz based HAART among Ugandan HIV patients with and without TB coinfection

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

   Neuropsychiatric disorders p
  No   Yes
N Median (IQR) N Median (IQR)
Day-3 37 1.61 (1.37-2.29) 125 2.29 (1.52-2.92) 0.02
week-1 28 1.86 (1.43-2.55) 80 2.26 (1.67-3.1) 0.13
week-2 40 1.69 (1.32-2.15) 111 2.22 (1.41-3.21) 0.03
week-4 40 1.57 (1.31-2.25) 110 2.49 (1.58-3.57) 0.002
week-6 36 1.8 (1.42-2.61) 86 2.37 (1.66-4.25) 0.008
week-8 45 1.64 (1.36-2.81) 121 2.31 (1.53-3.21) 0.09
week-12 41 1.84 (1.45-2.57) 101 2.57 (1.68-4.19) 0.03
  1. Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7,8 and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log transformed efavirenz concentration was used using independent sample T-test.